自冠状动脉造影术广泛开展以来,证实约70～90％的患者,冠脉内血栓是急性透壁性心肌梗塞的直接原因。所以溶栓治疗被作为治疗急性心肌梗塞的一种积极方法,其效果虽然各家意见不一,但多数资料证明,对抢救濒死心肌,缩小梗塞面积(主要为抢救心外膜下心肌),改善左室功能(约40％病例),降低病死率,以及近年作为冠状动脉旁路术的先前疗法都起着有益作用。一、溶栓疗法的原理是以纤维溶酶激活剂激活血栓中纤维蛋白溶解原,变为纤维蛋白溶解酶,而溶解血栓。此法曾在1959年提出,到1979年才推广应用于临床。目前最多应用的是链激酶(STK),主要给药途径为冠脉内及静脉内。冠脉内给药者,虽其冠脉 Since coronary angiography has been widely performed, it has been demonstrated that coronary thrombosis is the direct cause of acute transmural myocardial infarction in about 70 to 90% of patients. Therefore, thrombolytic therapy as an active treatment of acute myocardial infarction, although the effect of different opinions, but most data prove that the rescue of dying myocardium, reduce the infarct size (mainly to save the subepicardial myocardium) Improve left ventricular function (about 40% of cases), reduce mortality, and in recent years as coronary artery bypass surgery have played a beneficial role in the previous treatment. First, the principle of thrombolytic therapy is activated by fibrinolytic activator thrombus fibrinogen, into fibrinolytic enzyme, and dissolve thrombus. This method was proposed in 1959, until 1979, promote the clinical application. Currently the most used is streptokinase (STK), the main route of administration for intracoronary and intravenous. Coronary administration, although its coronary artery